We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

48 hedge funds and large institutions have $10.6M invested in Singular Genomics Systems, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less funds holding

Funds holding: 6248 (-14)

50% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 20

61% less capital invested

Capital invested by funds: $27.3M → $10.6M (-$16.7M)

93% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 15

Holders
48
Holders Change
-14
Holders Change %
-22.58%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
10
Reduced
20
Closed
15
Calls
$11K
Puts
Net Calls
+$11K
Net Calls Change
-$4K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$1.9M -$908K -48,867 -23%
AVM
2
Arch Venture Management
Illinois
$1.45M
PA
3
Perceptive Advisors
New York
$900K
UBS Group
4
UBS Group
Switzerland
$842K -$1.53M -82,344 -53%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$808K -$130 -7 -0%
Vanguard Group
6
Vanguard Group
Pennsylvania
$721K
CC
7
Casdin Capital
New York
$504K -$13.5K -727 -2%
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$487K +$38.3K +2,060 +12%
QM
9
QVIDTVM Management
Texas
$453K +$736K +39,613 New
BlackRock
10
BlackRock
New York
$330K -$4.46K -240 -0.8%
Millennium Management
11
Millennium Management
New York
$271K -$91.6K -4,929 -17%
O
12
OrbiMed
New York
$206K
AI
13
Acuitas Investments
Washington
$199K -$86.7K -4,667 -21%
Verition Fund Management
14
Verition Fund Management
Connecticut
$181K -$3.1K -167 -1%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$176K +$25.1K +1,353 +10%
PIM
16
Platinum Investment Management
Australia
$163K -$281K -15,121 -51%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$137K +$94.8K +5,103 +74%
TM
18
Tikvah Management
North Carolina
$121K
BCM
19
Bridgeway Capital Management
Texas
$106K
HighTower Advisors
20
HighTower Advisors
Illinois
$103K
TM
21
Triatomic Management
California
$74.2K
Renaissance Technologies
22
Renaissance Technologies
New York
$59K +$27.2K +1,464 +40%
Squarepoint
23
Squarepoint
New York
$51.1K -$3.73K -201 -4%
WC
24
Weil Company
California
$45K +$31K +1,667 +73%
State Street
25
State Street
Massachusetts
$42.9K -$16.7K -900 -19%

OMIC Hedge Fund Activity: Q3 2023 in Review

48 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q3 2023, worth a combined $10.6M — down 61% from $27.3M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of OMIC and 1 opened new positions — a net loss of 14 holders — while 20 trimmed existing stakes and 10 added.

The largest buyer was QVIDTVM Management, opening a new position worth an estimated $736K. The largest seller was UBS Group, cutting an estimated $1.53M.

  • 48 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q3 2023, down from 62 in Q2 2023.
  • Funds reported $10.6M of Singular Genomics Systems, Inc. Common Stock stock for Q3 2023, down 61% quarter-over-quarter.
  • 1 fund opened new Singular Genomics Systems, Inc. Common Stock positions in Q3 2023 and 15 closed out, a net change of -14 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q3 2023 was QVIDTVM Management, an estimated $736K added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q3 2023 was UBS Group, an estimated $1.53M sold.

Based on aggregated 13F filings for Q3 2023.